# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults

> **NCT04916431** · PHASE1 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** mRNA-6231

## Key facts

- **NCT ID:** NCT04916431
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-28
- **Primary completion:** 2022-08-02
- **Final completion:** 2022-08-02
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04916431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04916431, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04916431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*